Healthcare / Medical DevicesNasdaqCM
$1.97
-0.04 (-1.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-45.5M · quality 63.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$98M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-141.9%
↓Gross Margin
3.1%
↓Debt/Equity
0.72
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+15.9%
FCF CAGR
—
FCF margin
-95.0%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $33.6M · net income $-47.1M · FCF $-31.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $33.6M | $33.6M | $28.1M | $22.5M | $17.1M | $23.2M | $16.1M |
| Net Income | $-47.1M | $-47.1M | $-46.9M | $-52.5M | $-60.8M | $-73.5M | $-37.1M |
| EBITDA | $-42.7M | $-42.7M | $-46.6M | $-53.5M | $-60.4M | $-45.7M | $-29.0M |
| EPS | — | — | -1.08 | -1.22 | -1.43 | -3.94 | -126.11 |
| Gross Margin | 3.1% | 3.1% | -0.4% | -24.4% | -49.8% | — | — |
| Operating Margin | -141.1% | -141.1% | -178.0% | -251.2% | -369.0% | -203.3% | -190.0% |
| Net Margin | -140.3% | -140.3% | -167.2% | -233.0% | -354.9% | -316.5% | -230.6% |
| Balance Sheet | |||||||
| Debt/Equity | 0.72 | 0.72 | 0.08 | 0.06 | 0.05 | 0.00 | -0.20 |
| Current Ratio | 2.58 | 2.58 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-31.9M | $-31.9M | $-45.5M | $-46.9M | $-65.3M | $-58.2M | $-31.7M |
| Returns | |||||||
| ROE | -141.9% | -141.9% | -62.2% | -44.5% | -37.0% | -33.3% | 29.2% |
| Valuation | |||||||
| P/B | 2.64 | 2.64 | 0.60 | 0.34 | 0.33 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 19.7% | 19.7% | 24.6% | 31.4% | — | 44.5% | — |
| EPS Growth | — | — | 11.5% | 14.7% | — | 96.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.08 → n/d
Residual
-40.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.